Active Filter(s):
Details:
The financing will be used for the development of medicines that block notoriously difficult-to-drug protein targets with a new mode of action, selective termination of protein synthesis (STOPS) by using Initial's proprietary STOPS platform.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Apple Tree Partners
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 01, 2023